Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

PHASE1,PHASE2

Phase

COMPLETED

Status

Enrollment

INDUSTRY

Sponsor class

Conditions

COMBINATION_PRODUCT: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2
COMBINATION_PRODUCT: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2
COMBINATION_PRODUCT: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2
COMBINATION_PRODUCT: PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
COMBINATION_PRODUCT: PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
COMBINATION_PRODUCT: PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2

Rakuten Medical, Inc.